The effects of chronic methylphenidate treatment on growth and endocrine function in the developing rat

G. H. Greeley, J. S. Kizer

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    To study the possible adverse effects of chronic methylphenidate (Ritalin) upon growth and endocrine function in a developing animal, methylphenidate (1, 3, 10, 35 and 100 mg/kg b.wt.) was administered to neonatal rats. At various intervals, body weight, naso-anal length, age at vaginal opening, number of regular estrous cycles and serum levels of follicle-stimulating hormone, luteinizing hormone, growth hormone, prolactin and insulin were examined. 1) At 35 and 100 mg/kg b.wt., methylphenidate significantly decreases rate of skeletal growth and body weight gain in both females and males, largely due to its anorexigenic effects. At 100 mg/kg b.wt., the inhibitory effect on skeletal growth appears to be partly independent of anorexigenic properties. 2) Vaginal patency in females given 35 and 100 mg/kg b.wt. of methylphenidate during neonatal life is significantly delayed, and number of estrous cycles after cessation of chronic treatment is significantly reduced. In juvenile females, chronic methylphenidate significantly decreases the number of estrous cycles during treatment, with no significant differences between control and treated rats in cycle regularity after cessation of drug treatment. 3) In both males and females, chronic methylphenidate depresses serum prolactin levels at all doses, an effect which disappears after cessation of treatment. 4) At all doses, chronic methylphenidate significantly decreases basal serum insulin levels, but significantly enhances the insulin response to an acute glucose challenge. 5) Chronic methylphenidate treatment significantly depresses growth hormone levels in females, with no consistent effect in males. 6) In females, chronic methylphenidate has no consistent effect upon gonadotropin levels but significantly decreases luteinizing hormone and follicle-stimulating hormone levels in males, Thus, chronic methylphenidate during the neonatal period may significantly affect growth and endocrine function of the developing rat, but some of the adverse effects are transient and occur only at higher doses.

    Original languageEnglish (US)
    Pages (from-to)545-551
    Number of pages7
    JournalJournal of Pharmacology and Experimental Therapeutics
    Volume215
    Issue number3
    StatePublished - 1980

    Fingerprint

    Methylphenidate
    Growth
    Withholding Treatment
    Estrous Cycle
    Therapeutics
    Follicle Stimulating Hormone
    Insulin
    Luteinizing Hormone
    Prolactin
    Growth Hormone
    Serum
    Body Weight
    Gonadotropins
    Weight Gain

    ASJC Scopus subject areas

    • Pharmacology

    Cite this

    The effects of chronic methylphenidate treatment on growth and endocrine function in the developing rat. / Greeley, G. H.; Kizer, J. S.

    In: Journal of Pharmacology and Experimental Therapeutics, Vol. 215, No. 3, 1980, p. 545-551.

    Research output: Contribution to journalArticle

    @article{3909984ada5f41baac62883a1b58ecd6,
    title = "The effects of chronic methylphenidate treatment on growth and endocrine function in the developing rat",
    abstract = "To study the possible adverse effects of chronic methylphenidate (Ritalin) upon growth and endocrine function in a developing animal, methylphenidate (1, 3, 10, 35 and 100 mg/kg b.wt.) was administered to neonatal rats. At various intervals, body weight, naso-anal length, age at vaginal opening, number of regular estrous cycles and serum levels of follicle-stimulating hormone, luteinizing hormone, growth hormone, prolactin and insulin were examined. 1) At 35 and 100 mg/kg b.wt., methylphenidate significantly decreases rate of skeletal growth and body weight gain in both females and males, largely due to its anorexigenic effects. At 100 mg/kg b.wt., the inhibitory effect on skeletal growth appears to be partly independent of anorexigenic properties. 2) Vaginal patency in females given 35 and 100 mg/kg b.wt. of methylphenidate during neonatal life is significantly delayed, and number of estrous cycles after cessation of chronic treatment is significantly reduced. In juvenile females, chronic methylphenidate significantly decreases the number of estrous cycles during treatment, with no significant differences between control and treated rats in cycle regularity after cessation of drug treatment. 3) In both males and females, chronic methylphenidate depresses serum prolactin levels at all doses, an effect which disappears after cessation of treatment. 4) At all doses, chronic methylphenidate significantly decreases basal serum insulin levels, but significantly enhances the insulin response to an acute glucose challenge. 5) Chronic methylphenidate treatment significantly depresses growth hormone levels in females, with no consistent effect in males. 6) In females, chronic methylphenidate has no consistent effect upon gonadotropin levels but significantly decreases luteinizing hormone and follicle-stimulating hormone levels in males, Thus, chronic methylphenidate during the neonatal period may significantly affect growth and endocrine function of the developing rat, but some of the adverse effects are transient and occur only at higher doses.",
    author = "Greeley, {G. H.} and Kizer, {J. S.}",
    year = "1980",
    language = "English (US)",
    volume = "215",
    pages = "545--551",
    journal = "Journal of Pharmacology and Experimental Therapeutics",
    issn = "0022-3565",
    publisher = "American Society for Pharmacology and Experimental Therapeutics",
    number = "3",

    }

    TY - JOUR

    T1 - The effects of chronic methylphenidate treatment on growth and endocrine function in the developing rat

    AU - Greeley, G. H.

    AU - Kizer, J. S.

    PY - 1980

    Y1 - 1980

    N2 - To study the possible adverse effects of chronic methylphenidate (Ritalin) upon growth and endocrine function in a developing animal, methylphenidate (1, 3, 10, 35 and 100 mg/kg b.wt.) was administered to neonatal rats. At various intervals, body weight, naso-anal length, age at vaginal opening, number of regular estrous cycles and serum levels of follicle-stimulating hormone, luteinizing hormone, growth hormone, prolactin and insulin were examined. 1) At 35 and 100 mg/kg b.wt., methylphenidate significantly decreases rate of skeletal growth and body weight gain in both females and males, largely due to its anorexigenic effects. At 100 mg/kg b.wt., the inhibitory effect on skeletal growth appears to be partly independent of anorexigenic properties. 2) Vaginal patency in females given 35 and 100 mg/kg b.wt. of methylphenidate during neonatal life is significantly delayed, and number of estrous cycles after cessation of chronic treatment is significantly reduced. In juvenile females, chronic methylphenidate significantly decreases the number of estrous cycles during treatment, with no significant differences between control and treated rats in cycle regularity after cessation of drug treatment. 3) In both males and females, chronic methylphenidate depresses serum prolactin levels at all doses, an effect which disappears after cessation of treatment. 4) At all doses, chronic methylphenidate significantly decreases basal serum insulin levels, but significantly enhances the insulin response to an acute glucose challenge. 5) Chronic methylphenidate treatment significantly depresses growth hormone levels in females, with no consistent effect in males. 6) In females, chronic methylphenidate has no consistent effect upon gonadotropin levels but significantly decreases luteinizing hormone and follicle-stimulating hormone levels in males, Thus, chronic methylphenidate during the neonatal period may significantly affect growth and endocrine function of the developing rat, but some of the adverse effects are transient and occur only at higher doses.

    AB - To study the possible adverse effects of chronic methylphenidate (Ritalin) upon growth and endocrine function in a developing animal, methylphenidate (1, 3, 10, 35 and 100 mg/kg b.wt.) was administered to neonatal rats. At various intervals, body weight, naso-anal length, age at vaginal opening, number of regular estrous cycles and serum levels of follicle-stimulating hormone, luteinizing hormone, growth hormone, prolactin and insulin were examined. 1) At 35 and 100 mg/kg b.wt., methylphenidate significantly decreases rate of skeletal growth and body weight gain in both females and males, largely due to its anorexigenic effects. At 100 mg/kg b.wt., the inhibitory effect on skeletal growth appears to be partly independent of anorexigenic properties. 2) Vaginal patency in females given 35 and 100 mg/kg b.wt. of methylphenidate during neonatal life is significantly delayed, and number of estrous cycles after cessation of chronic treatment is significantly reduced. In juvenile females, chronic methylphenidate significantly decreases the number of estrous cycles during treatment, with no significant differences between control and treated rats in cycle regularity after cessation of drug treatment. 3) In both males and females, chronic methylphenidate depresses serum prolactin levels at all doses, an effect which disappears after cessation of treatment. 4) At all doses, chronic methylphenidate significantly decreases basal serum insulin levels, but significantly enhances the insulin response to an acute glucose challenge. 5) Chronic methylphenidate treatment significantly depresses growth hormone levels in females, with no consistent effect in males. 6) In females, chronic methylphenidate has no consistent effect upon gonadotropin levels but significantly decreases luteinizing hormone and follicle-stimulating hormone levels in males, Thus, chronic methylphenidate during the neonatal period may significantly affect growth and endocrine function of the developing rat, but some of the adverse effects are transient and occur only at higher doses.

    UR - http://www.scopus.com/inward/record.url?scp=0019180042&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0019180042&partnerID=8YFLogxK

    M3 - Article

    C2 - 7003098

    AN - SCOPUS:0019180042

    VL - 215

    SP - 545

    EP - 551

    JO - Journal of Pharmacology and Experimental Therapeutics

    JF - Journal of Pharmacology and Experimental Therapeutics

    SN - 0022-3565

    IS - 3

    ER -